Literature DB >> 1527337

The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies.

J M Gwaltney1, W M Scheld, M A Sande, A Sydnor.   

Abstract

Pretreatment sinus puncture was performed on 339 patients with acute community-acquired sinusitis (ACAS) between 1975 and 1990. Bacterial species recovered in titers of greater than or equal to 10(4) colony-forming units per milliliter (CFU/ml) from 383 sinus aspirates included Streptococcus pneumoniae, 92 (41%); Haemophilus influenzae, 79 (35%); anaerobes, 17 (7%); streptococcal species, 16 (7%); Moraxella catarrhalis, 8 (4%); Staphylococcus aureus, 7 (33%); and other, 8 (4%). Viruses (rhinovirus, parainfluenza virus, and influenza virus) and fungi (Aspergillus, zygomycoses, Phaeohyphomycis, Pseudallescheria, and Hyalohyphomycis) have also been reported to cause ACAS. Posttreatment sinus puncture was performed on 220 of the 339 patients in six studies to evaluate efficacy of selected antimicrobial agents in producing bacteriologic cure. Ampicillin, 500 mg four times daily; amoxicillin, 500 mg three times daily; trimethoprim-sulfamethoxazole, twice a day; cefaclor, 500 mg four times daily; bacampicillin, 800 mg twice a day; cyclacillin, 500 mg three times a day; cefuroxime axetil, 250 mg twice daily; amoxicillin-clavulanate, 500/125 three times daily; and loracarbef 400 mg twice daily, given in 10-day courses, produced bacteriologic cure in more than 90% of patients. Early studies were done before beta-lactamase-producing strains of H. influenzae were a frequent cause of ACAS in Charlottesville. Management of therapeutic failures is a difficult problem for which diagnostic and therapeutic sinus puncture and lavage, prolonged antimicrobial therapy, steroid therapy, and evaluation of allergy, immunodeficiency, and surgically correctable lesions of the osteomeatal complex are recommended.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527337     DOI: 10.1016/0091-6749(92)90169-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  31 in total

Review 1.  Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.

Authors:  Drosos E Karageorgopoulos; Konstantina P Giannopoulou; Alexandros P Grammatikos; George Dimopoulos; Matthew E Falagas
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

2.  Acute sinusitis.

Authors:  Graham Worrall
Journal:  Can Fam Physician       Date:  2011-05       Impact factor: 3.275

Review 3.  The role of allergy in sinus disease. Children and adults.

Authors:  Z Pelikan
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 8.667

Review 4.  Canadian guidelines for acute bacterial rhinosinusitis: clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

Review 5.  Diagnosis and Management of Rhinosinusitis: Highlights from the 2015 Practice Parameter.

Authors:  Kathleen Dass; Anju Tripathi Peters
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

6.  Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.

Authors:  J M Gwaltney; S Savolainen; P Rivas; P Schenk; W M Scheld; A Sydnor; C Keyserling; A Leigh; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 7.  Current diagnosis and management of sinusitis.

Authors:  L R Willett; J L Carson; J W Williams
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

8.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

9.  Current management of upper respiratory tract and head and neck infections.

Authors:  Itzhak Brook
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-05       Impact factor: 2.503

Review 10.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Authors:  Jack B Anon; Michael R Jacobs; Michael D Poole; Paul G Ambrose; Mark S Benninger; James A Hadley; William A Craig
Journal:  Otolaryngol Head Neck Surg       Date:  2004-01       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.